This panel was the one showing lower coverage for all genes, probably due to the fact that all 16 samples were multiplexed on a V2 kit (8Gb per run; 150x2 cycles), whereas for the other three panels, 8 samples were multiplexed on a V3 kit (14Gb per run; 250x2 cycles); this might be the reason why FLT3-ITDs detected with low VAF in other panels, were not called with SureSeqTM AML panel. This evidence concerns the gene FLT3 and acute myeloid leukemia.